Drug Development

Listings
  • L929/A

    L929/A

    Drug Development Shirley (New York) September 30, 2026 1.00 Dollar US$

    This Adriamycin-resistant cell line has been developed by exposure of the parent L929 murine fibroblast cell line to increasing concentrations of doxorubicin in-vitro. L929/A cells can be used in the development of novel anti-cancer treatments. Resis...

  • NMuMG

    NMuMG

    Drug Development Shirley (New York) September 30, 2026 1.00 Dollar US$

    Initiated from the mammary gland tissue of an adult NAMRU mouse and one of a series of epithelial cell lines derived from normal glandular tissue of mice. The cells exhibit many ultrastructural features of secretory epithelium as well as desmosomes o...

  • Hepa 1-clc7

    Hepa 1-clc7

    Drug Development Shirley (New York) September 30, 2026 1.00 Dollar US$

    Species: mouse, C57L; Tissue: liver; Tumor: hepatoma, BW7756; Derived from: Hepa-1cl, cloned from the Hepa-1 cell line https://www.creative-bioarray.com/Hepa-1-clc7-CSC-6264W-item-1508.htm

  • MPP 89

    MPP 89

    Drug Development Shirley (New York) September 30, 2026 1.00 Dollar US$

    Cat.No. CSC-6299W Description Species: human male 67 years old; Tissue: pleural effusion; Tumor: mesothelioma Species Homo sapiens (Human) Source Pleural Effusion https://www.creative-bioarray.com/MPP-89-CSC-6299W-item-1022.htm